Polpharma SA
http://www.polpharma.pl/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Polpharma SA
Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets
Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.
European Regulator Pulls Marketing Authorizations For Tecfidera Generics
In a blow to several generics firms – albeit one telegraphed by a decision handed down nine months ago – the European Commission has ordered the removal of marketing authorizations for generic versions of Biogen’s MS brand, Tecfidera.
Formycon Announces Health Canada Approval Of Ranibizumab Biosimilar
Formycon has announced the approval of its biosimilar ranibizumab by Health Canada, with commercial launch by Teva expected to begin in Q1 next year.
EMA Says Yes To Janssen’s Talvey & 13 Other Drugs
Fourteen new products could be approved in the EU soon, after the European Medicines Agency gave them the thumbs up.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Polpharma Biologics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice